Aduro Biotech Announces Upcoming Data Presentations at the 2018 American Association for Cancer Research Annual Meeting
March 14 2018 - 4:31PM
Aduro Biotech, Inc. (Nasdaq:ADRO), today announced three
preclinical data presentations highlighting its STING and antibody
product candidates will be delivered at the 2018 American
Association for Cancer Research Annual Meeting taking place in
Chicago, IL, April 14 through April 18, 2018.
Abstract 631:
|
Intratumoral activation of STING with a
synthetic cyclic dinucleotide elicits antitumor CD8 T-cell immunity
that effectively combines with checkpoint inhibitors |
|
|
Date/Time: |
Sunday, April 15, 1:00
p.m. to 5:00 p.m. Central Time |
Session: |
Modifiers of the Tumor
Microenvironment 1 |
Location: |
McCormick Place South,
Exhibit Hall A |
|
Poster section 28;
Board number 8 |
Abstract
1702: |
Assessment of
pharmacology and toxicology of anti-CTLA-4 antibody (ADU-1604) in
non-human primates and evaluation of local anti-CTLA-4
application |
|
|
Date/Time: |
Monday, April 16, 8:00
a.m. to 12:00 p.m. Central Time |
Session: |
Immune Checkpoints
1 |
Location: |
McCormick Place South,
Exhibit Hall A |
|
Poster section 31;
Board number 27 |
Abstract
3780: |
Preclinical
pharmacokinetics, pharmacodynamics and safety of BION-1301, a
first-in-class antibody targeting APRIL for the treatment of
multiple myeloma |
|
|
Date/Time: |
Tuesday, April 17, 8:00
a.m. to 12:00 p.m. Central Time |
Session: |
Immunomodulatory Agents
and Interventions 1 |
Location: |
McCormick Place South,
Exhibit Hall A |
|
Poster section 32;
Board number 30 |
To view these abstracts, please visit the AACR website located
at http://www.aacr.org/Meetings
About Aduro Aduro Biotech, Inc. is an
immunotherapy company focused on the discovery, development and
commercialization of therapies that transform the treatment of
challenging diseases. Aduro's technology platforms, which are
designed to harness the body's natural immune system, are being
investigated in cancer indications and have the potential to expand
into autoimmune and infectious diseases. Aduro's STING Pathway
Activator platform is designed to activate the STING receptor in
immune cells, resulting in a potent tumor-specific immune response.
ADU-S100 is the first STING Pathway Activator compound to enter the
clinic and is currently being evaluated in both a Phase 1
monotherapy study as well as a Phase 1b combination study with an
anti-PD1 immune checkpoint inhibitor. Aduro’s B-select monoclonal
antibody platform is comprised of a number of immune modulating
assets in research and development, including BION-1301, an
anti-APRIL antibody. Aduro's pLADD program is based on proprietary
attenuated strains of Listeria that have been engineered to express
tumor neoantigens that are specific to an individual patient’s
tumor. Other Listeria strains for lung and prostate cancers are
being advanced by a partner. Aduro is collaborating with leading
global pharmaceutical companies to expand its products and
technology platforms. For more information, please visit
www.aduro.com.
Cautionary Note on Forward-Looking StatementsThis press release
contains forward-looking statements for purposes of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements regarding our
intentions or current expectations concerning, among other things,
the potential for our technology platforms, plans, and the
potential for eventual regulatory approval of our product
candidates. In some cases, you can identify these statements by
forward-looking words such as “may,” “will,” “continue,” “plan,”
“anticipate,” “intend,” “could,” “project,” “seek,” “expect,”
“position” or the negative or plural of these words or similar
expressions. Forward-looking statements are not guarantees of
future performance and are subject to risks and uncertainties that
could cause actual results and events to differ materially from
those anticipated, including, but not limited to, our history of
net operating losses and uncertainty regarding our ability to
achieve profitability, our ability to develop and commercialize our
product candidates, our ability to use and expand our technology
platforms to build a pipeline of product candidates, our ability to
obtain and maintain regulatory approval of our product candidates,
our ability to operate in a competitive industry and compete
successfully against competitors that have greater resources than
we do, our reliance on third parties, and our ability to obtain and
adequately protect intellectual property rights for our product
candidates. We discuss many of these risks in greater detail
under the heading “Risk Factors” contained in our annual report on
Form 10--K for the year ended December 31, 2017, which is on file
with the Securities and Exchange Commission. Any forward-looking
statements that we make in this press release speak only as of the
date of this press release. We assume no obligation to update our
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Contact: |
|
Media Contact: |
Jennifer Lew
|
|
Aljanae Reynolds |
Chief Financial
Officer |
|
510 809 2452 |
510 809-4816
|
|
press@aduro.com |
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Sep 2023 to Sep 2024